Friday, March 16, 2012
Written by William C. Phelps, PhD, director of preclinical and translational cancer research, American Cancer Society, December 14, 2011
In the 1960s two young scientists in Philadelphia, Dr. Peter Nowell from the University of Pennsylvania and Dr. David Hungerford from Fox Chase Cancer Center, spent their days peering through microscopes at white blood cells. They noticed that when they stained cells from patients with chronic myeloid leukemia (aka chronic myelogenous leukemia, or CML), they would very often see an odd, minute chromosome in addition to the normal set.
We know today that this was a landmark observation. Dr. Nowell and Dr. Hungerford named their discovery the “Philadelphia Chromosome” in keeping with the tradition of the day, and it soon became an important way to diagnose CML.
In the 1970s, Dr. Janet Rowley at the University of Chicago used newly-developed techniques that highlighted different regions of chromosomes to look more carefully at the Philadelphia Chromosome. She determined that they looked odd because two large pieces of two different chromosomes had changed places. But the significance of that translocation wasn’t immediately apparent.
At the Massachusetts Institute of Technology in the 1980s, Nobel Laureate Dr. David Baltimore followed up on Dr. Rowley’s observations to make a critical discovery about what causes CML. His laboratory was able to show that one of the results of the exchange of chromosomal material was the creation of a completely new gene, BCR-Abl, which was only found in CML cells. Dr. Baltimore went on to show that the BCR-Abl protein causes CML in laboratory and animal models. Knowing what causes CML provided the platform for the next major discovery in the treatment of this form of leukemia, which is most commonly found in older adults.
Dr. Brian Druker at Oregon Health and Science University combined perseverance, innovation, and personal commitment to cancer patients to make the next major breakthrough in the 1990s. One of the most critical challenges that he faced was not scientific, but economic.
At the time, the number of patients afflicted with CML in the U.S. was thought to be too small to entice major pharmaceutical companies to develop a drug. Regardless, Dr. Druker was able to convince Novartis (then called Ciba-Geigy) to allow him to screen some of the compounds in their huge chemical collections. Remarkably, he discovered a drug that blocked the activity of the BCR-Abl protein.
After another decade of testing and clinical trials, Gleevec (imatinib mesylate) was approved by the Food and Drug Administration for treatment of CML in 2001. Together with other, later drugs which target the BCR-Abl protein, Gleevec has transformed CML from a lethal diagnosis to a manageable disease for more than 90 percent of patients.
Effective treatment of CML has undoubtedly saved thousands of lives, but it took four decades of discovery in four different parts of the country to make this possible. No matter how much we want a cure for cancer tomorrow, the history of science has taught us that it takes time. Even a brief examination of the major breakthroughs in cancer medicine reveals that the major discoveries were only possible because of a series of advances, painstakingly accumulated over many decades.
In every case, success results from the marriage of hard work and innovation nurtured by the element of time. (Money is crucial, too, of course. Without it, research can’t happen at all, and cutting funding only slows the development of new treatments.)
Discoveries made in the 1990s set the stage for the advances in targeted therapies against a broad range of cancers, including melanoma, lung cancer, and leukemia, for which we’ve seen major advancements during just the past year. These promising paths need the time — and dollars, of course — to find their greatest benefits for cancer patients during the next decade. It really is about time.
November 23, 2013
Since its founding in 1997, Golfers Against Cancer has had one goal: to fund cancer research. Virtually all the money raised in GAC tournaments and events goes directly to cancer research organizations, including the CHRISTUS Stehlin Foundation.
August 2, 2013
The 14th Annual Luci Bonneau Memorial Striking Against Breast Cancer Mixed Doubles Bowling Tournament is one of the most prestigious doubles events in America. The tournament includes a Pro-Am - your chance to bowl with the pros to cure breast cancer!
October 19, 2013 | 7:00 p.m.
Get ready to disco and dance the night away at The Friends of CHRISTUS Stehlin Gala! Premiering “STAYIN’ ALIVE,” The Greatest Bee Gees Tribute Band with Members of the Houston Symphony Orchestra and America’s first Mash Up Group, “THE COMPANY MEN.”
May 4, 2013
On May 4th, 2013, young women will take the field for the first time in an exciting powder puff football game with teams comprised of some of best and brightest in Austin. The game is designed to bring the passion and spirit of young community leaders together to support Young Texans Against Cancer.
“Compared with other anticancer drugs at similar stages of development, camptothecins have demonstrated a much higher anticancer activity. Camptothecins can be envisioned as the ultimate anticancer drug when fully developed.”
National Academy of Science, 1995
CHRISTUS Stehlin Foundation for Cancer Research will join CHRISTUS St. Catherine and CHRISTUS St. John in a new partnership with Houston Methodist.
There are currently 13.7 million cancer survivors in the United States and the number is expected to rise by 31 percent to 18 million by 2022, according to a new report. >> Click article title for more.